BIG
RCUS icon

Brooklyn Investment Group’s Arcus Biosciences RCUS Stock Holding History

Brooklyn Investment Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-362
Closed -$2.95K – 2208
2025
Q2 		$2.95K Buy
362
+213
+143% +$1.82K ﹤0.01% 2654
2025
Q1 		$1.17K Buy
149
+148
+14,800% +$1.72K ﹤0.01% 2312
2024
Q4 		$15 Buy
+1
New +$16 ﹤0.01% 1901

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brooklyn Investment Group's RCUS Position: Q3 2025 in Review

Brooklyn Investment Group sold out of Arcus Biosciences (RCUS) in Q3 2025, closing a stake of 362 shares — an estimated $2.95K sold.

Brooklyn Investment Group first reported a position in RCUS in Q4 2024 and held it in 3 quarters. The position peaked at $2.95K in Q2 2025. 190 funds tracked by Wall St. Rank hold RCUS as of Q3 2025.

  • Brooklyn Investment Group reported no remaining Arcus Biosciences position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 362 Arcus Biosciences shares in Q3 2025, an estimated $2.95K.
  • Brooklyn Investment Group first reported a position in Arcus Biosciences in Q4 2024 and held it in 3 quarters.
  • Brooklyn Investment Group's Arcus Biosciences position peaked at $2.95K in Q2 2025.
  • 190 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.